| S3868 |
Harmine
|
Harmine (Telepathine), a fluorescent harmala alkaloid belonging to the beta-carboline family of compounds, is a highly cell-permeant and competitive inhibitor of ATP binding to the kinase pocket of DYRK1A, with about 60-fold higher IC50 value for DYRK2. This compound also inhibits monoamine oxidases (MAOs), PPARγ and cdc-like kinases (CLKs). It inhibits 5-HT2A serotonin receptor with Ki of 397 nM.
|
-
Cell Rep Med, 2025, 6(8):102297
-
Bone Res, 2025, 13(1):62
-
J Cell Mol Med, 2025, 29(15):e70774
|
|
| S3834 |
Astaxanthin
|
Astaxaxanthin (β-Carotene-4,4'-dione, Trans-Astaxanthin), a xanthophyll carotenoid, is a nutrient with unique cell membrane actions and diverse clinical benefits with excellent safety and tolerability. This compound, a red dietary carotenoid isolated from Haematococcus pluvialis, is a modulator of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity.
|
-
Int Immunopharmacol, 2023, 119:110159
-
J Gerontol A Biol Sci Med Sci, 2022, 77-8:1485-1493
-
Aging (Albany NY), 2019, 11(22):10513-10531
|
|
| S7955 |
EPI-001
|
EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ∼6 μM and a selective PPAR-gamma modulator.
|
-
Int J Biol Macromol, 2024, 278(Pt 3):134844
-
Nat Struct Mol Biol, 2023, 30(12):1958-1969
-
Int J Mol Sci, 2023, 24(4)3823
|
|
| S6906 |
Capric acid
|
Capric acid (DA, Decanoic acid, Decylic acid), a component of medium-chain triclycerides occurring naturally in coconut oil and palm kernel oil, contributes to seizure control through direct AMPA receptor inhibition. This compound is also a modulating ligand for PPARs. Due to its specific melting range the product may be solid, liquid, a solidified melt or a supercooled melt.
|
-
Pharmaceuticals (Basel), 2023, 16(5)692
|
|
| E1695 |
9-cis-Retinoic acid
|
9-cis-Retinoic acid (Alitretinoin, ALRT 1057) is an active metabolite of vitamin A that functions as a high-affinity ligand for retinoid X receptors (RXRs) and also activates retinoic acid receptors (RARs). It inhibits adipogenesis by activating RXR while simultaneously decreasing RXRα and PPARγ levels in an RXR activation-independent manner.
|
|
|